Cargando…

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights

Combating acquired drug resistance of EGFR tyrosine kinase (TK) is a great challenge and an urgent necessity in the management of non-small cell lung cancers. The advanced EGFR (L858R/T790M/C797S) triple mutation has been recently reported, and there have been no specific drugs approved for this str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suriya, Utid, Mahalapbutr, Panupong, Wimonsong, Watchara, Yotphan, Sirilata, Choowongkomon, Kiattawee, Rungrotmongkol, Thanyada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788584/ https://www.ncbi.nlm.nih.gov/pubmed/36558033 http://dx.doi.org/10.3390/molecules27248901

Ejemplares similares

Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site
por: Suriya, Utid, et al.
Publicado: (2022)

Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
por: Aiebchun, Thitinan, et al.
Publicado: (2021)

Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors
por: Hengphasatporn, Kowit, et al.
Publicado: (2023)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2020)

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
por: Sanachai, Kamonpan, et al.
Publicado: (2023)

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
por: Todsaporn, Duangjai, et al.
Publicado: (2023)

Fisetin glycosides synthesized by cyclodextrin glycosyltransferase from Paenibacillus sp. RB01: characterization, molecular docking, and antioxidant activity
por: Lorthongpanich, Nattawadee, et al.
Publicado: (2022)

Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2′-O-Methyltransferase
por: Mahalapbutr, Panupong, et al.
Publicado: (2020)

In silico design of EGFR(L858R/T790M/C797S) inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations
por: Hadni, Hanine, et al.
Publicado: (2022)

In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach
por: Thirunavukkarasu, Muthu Kumar, et al.
Publicado: (2021)

Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations
por: Mahalapbutr, Panupong, et al.
Publicado: (2019)

Pyrazolones Potentiate Colistin Activity against MCR-1-Producing Resistant Bacteria: Computational and Microbiological Study
por: Hanpaibool, Chonnikan, et al.
Publicado: (2023)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
por: Choi, Geunho, et al.
Publicado: (2021)

Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors
por: Sangpheak, Kanyani, et al.
Publicado: (2019)

Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling
por: Mahalapbutr, Panupong, et al.
Publicado: (2022)

Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/ cisT790M/cisC797S NSCLC: A Case Report
por: Lee, Bing-Jie, et al.
Publicado: (2022)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
por: Fawwaz, Muammar, et al.
Publicado: (2021)

Enhanced Solubility and Anticancer Potential of Mansonone G By β-Cyclodextrin-Based Host-Guest Complexation: A Computational and Experimental Study
por: Mahalapbutr, Panupong, et al.
Publicado: (2019)

Aurisin A Complexed with 2,6-Di-O-methyl-β-cyclodextrin Enhances Aqueous Solubility, Thermal Stability, and Antiproliferative Activity against Lung Cancer Cells
por: Charoenwongpaiboon, Thanapon, et al.
Publicado: (2022)

Enhancing solubility and stability of sorafenib through cyclodextrin-based inclusion complexation: in silico and in vitro studies
por: Aman, Aamir, et al.
Publicado: (2023)

Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
por: Leechaisit, Ronnakorn, et al.
Publicado: (2023)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
por: Zhao, Jing, et al.
Publicado: (2018)

Theoretical studies on RNA recognition by Musashi 1 RNA-binding protein
por: Darai, Nitchakan, et al.
Publicado: (2022)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Proteomics and Molecular Docking Analyses Reveal the Bio-Chemical and Molecular Mechanism Underlying the Hypolipidemic Activity of Nano-Liposomal Bioactive Peptides in 3T3-L1 Adipocytes
por: Krobthong, Sucheewin, et al.
Publicado: (2023)

Atomistic mechanisms underlying the activation of the G protein-coupled sweet receptor heterodimer by sugar alcohol recognition
por: Mahalapbutr, Panupong, et al.
Publicado: (2019)

Publisher Correction: Atomistic mechanisms underlying the activation of the G protein-coupled sweet receptor heterodimer by sugar alcohol recognition
por: Mahalapbutr, Panupong, et al.
Publicado: (2019)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
por: Somboon, Tuanjai, et al.
Publicado: (2021)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
por: Chang, Yuan, et al.
Publicado: (2022)

Rhodium-catalyzed selenylation and sulfenylation of quinoxalinones ‘on water’
por: Lalji, Ram Sunil Kumar, et al.
Publicado: (2023)

Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
por: Baba, Keisuke, et al.
Publicado: (2019)

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
por: Hu, Peng, et al.
Publicado: (2016)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR(L858R/T790M/C797S) Inhibitors: A Molecular Dynamics Simulation Study
por: E, Jingwen, et al.
Publicado: (2020)

In vitro and in silico studies of 7′′,8′′-buddlenol D anti-inflammatory lignans from Carallia brachiata as p38 MAP kinase inhibitors
por: Nalinratana, Nonthaneth, et al.
Publicado: (2023)

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
por: Kim, Ji Yeon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aqo58r42rl80llca7bf406efqv